A phase i study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors

Chemotherapy

Volumn 55, Issue 6, 2009, Pages 441-445

  Morgensztern, Daniel ^a   Baggstrom, Maria Q ^a   Pillot, Giancarlo ^a   Tan, Benjamin ^a   Fracasso, Paula ^b   Suresh, Rama ^a   Wildi, Jonathan ^a   Govindan, Ramaswamy ^a  

^a Washington University in St Louis School of Medicine

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Doxorubicin; Irinotecan; Phase I study

Indexed keywords

DOXORUBICIN; IRINOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GALLBLADDER CANCER; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 71249102578     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000264925     Document Type: Article

References (26)

1. Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, et al: Sequential oral 9- nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther 2006; 5: 2130-2137.
2. Hammond LA, Eckardt JR, Ganapathi R, Burris HA, Rodriguez GA, Eckhardt SG, et al: A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clin Cancer Res 1998; 4: 1459-1467.
3. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7: 2182-2194.
4. Sadahiro S, Suzuki T, Maeda Y, Ishikawa K, Yasuda S, Makuuchi H, et al: Phase I/II study of 24-hour infusion of irinotecan combined with oral UFT for metastatic colorectal cancer. Chemotherapy 2008; 54: 140-146.
5. Tsavaris N, Kosmas C, Skopelitis H, Papdonio N, Polyzos A, Zografos G, et al: Sequential administration of 5-fluorouracil (5-FU)/ leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study. Chemotherapy 2007; 53: 282-291.
6. Gabizon AA, Shmeeda H, Zalipsky S: Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006; 16: 175-183.
7. Gabizon A, Shmeeda H, Barenholz Y: Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42: 419-436.
8. Allen TM, Martin FJ: Advantages of liposomal delivery systems for anthracyclines. Semin Oncol 2004; 31(suppl 13):5-15.
9. Bogner JR, Kronawitter U, Rolinski B, Truebenbach K, Goebel FD: Liposomal doxorubicin in the treatment of advanced AIDSrelated Kaposi sarcoma. J Acquir Immune Defic Syndr 1994; 7: 463-468.
10. Perez-Lopez ME, Curiel T, Gomez JG, Jorge M: Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 2007; 18: 611-617.
11. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-449.
12. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K: Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer 1992; 50: 760-766.
13. Eder JP, Chan V, Wong J, Wong YW, Ara G, Northey D, et al: Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo. Cancer Chemother Pharmacol 1998; 42: 327-335.
14. Dunphy FR, Cantrell C, Dunleavy T, Visconti J, Richart J, Pincus S, et al: Phase I and pharmacokinetic (PK) study of doxil (D) and irinotecan (I) in advanced cancer patients (abstract 404). Proc Am Soc Clin Oncol 2001; 20.
15. Therasse P, Arbuck SG, Eisenhauser EA, Wangers J, Kaplan RS, Rubinstein L, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
16. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al:. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
17. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung can - cer. N Engl J Med 2002; 346: 85-91.
18. Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, et al: Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 1994; 12: 1833-1841. (Pubitemid 24349385)
19. Karato A, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, et al: Phase I study of CPT- and etoposide in patients with refractory solid tumors. J Clin Oncol 1993; 11: 2030-2035.
20. Hwang JJ, Marshall JL, Rizvi N: Combined inhibition of topoisomerases: a phase I study of irinotecan and epirubicin. Oncology (Williston Park) 2003; 17(suppl 5):46-51.
21. Tolcher AW, O'Shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E, et al: A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin Cancer Res 1997; 3: 755-760.
22. Mirchandani D, Hochster H, Hamilton A, Liebes L, Yee H, Curtin JP, et al: Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res 2005; 11: 5912-5919.
23. Seiden MV, Ng SW, Supko JG, Ryan DP, Clark JW, Lynch T, et al: A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Clin Cancer Res 2002; 8: 691-697.
24. Nishimura S, Tsuda H, Hashiguchi Y, Kokawa K, Nishimura R, Ishiko O, et al: Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis. Int J Gynecol Cancer 2007; 17: 159-163.
25. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
26. Von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-667.